Hai Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hai Yan has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Bill H. Diplas
Department of Pathology, Duke University, Durham, North Carolina
166 shared publications - Betty Rouaisnel
IGMM, Univ Montpellier, CNRS , Montpellier
159 shared publications - Bofu Huang
Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
159 shared publications - Cihangir Duy
Cancer Signaling and Epigenetics Program, Cancer Epigenetic Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania
159 shared publications - Harley I. Kornblum
Department of Psychiatry and Human Behavior, University of California, Los Angeles , Los Angeles, CA 90095
159 shared publications - John G. Doench
Genetic Perturbation Platform, Broad Institute, Cambridge, USA
159 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9: from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Genomic regions marked by increased trimethyl-H3K4 are enriched in IDH1-mutant glioma MCTS lines when compared to IDH1-wild-type MCTS lines.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9: from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Genomic regions marked by increased trimethyl-H3K4 are enriched in IDH1-mutant glioma MCTS lines when compared to IDH1-wild-type MCTS lines.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Transcriptional analysis of primary AML patient samples.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Transcriptional analysis of primary AML patient samples.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Supplementary Table S3 shows the rank order list of genes targeted by sgRNAs enriched in the genome-wide CRISPR/Cas9 knockout screens.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Supplementary Table S3 shows the rank order list of genes targeted by sgRNAs enriched in the genome-wide CRISPR/Cas9 knockout screens.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Supplementary Table S2 shows the quantification of (R)-2HG in TF-1 cells.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Supplementary Table S2 shows the quantification of (R)-2HG in TF-1 cells.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Supplementary Table S9 shows the gene set enrichment analysis gene set that corresponds to Figure S6A.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Supplementary Table S9 shows the gene set enrichment analysis gene set that corresponds to Figure S6A.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Characterization of isogenic IHA cell lines.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Characterization of isogenic IHA cell lines.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
5mC levels in primary AML and primary glioma samples and in MCTS lines.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
5mC levels in primary AML and primary glioma samples and in MCTS lines.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
ChIP-seq analysis of primary AML patient samples.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
ChIP-seq analysis of primary AML patient samples.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Inhibition of KDM5 enzymes by the (R)- and (S)-enantiomers of 2-hydroxyglutarate.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Inhibition of KDM5 enzymes by the (R)- and (S)-enantiomers of 2-hydroxyglutarate.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Supplementary Table S5 shows the rank order list of genes targeted by sgRNAs enriched in the custom minipool CRISPR/Cas9 knockout screens.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers
Supplementary Table S5 shows the rank order list of genes targeted by sgRNAs enriched in the custom minipool CRISPR/Cas9 knockout screens.